Literature DB >> 8112883

Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas.

R Lotan1, H Ito, W Yasui, H Yokozaki, D Lotan, E Tahara.   

Abstract

The expression of lactoside-binding lectin L-31 was analyzed in normal mucosa and in primary and metastatic gastric carcinomas. Immunoblotting revealed L-31 lectin in extracts of normal and malignant gastric tissues from 26 patients. The L-31 level was higher in tumor than in normal tissue in 9/26 cases, similar in 14/26 cases, and lower in 3/26 cases. Anti-L-31 monoclonal antibodies (MAbs) were used in immunohistochemical analyses to compare lectin expression in specimens of primary gastric carcinomas and adjacent normal mucosa from 39 patients and in specimens of metastases and the corresponding primary gastric carcinomas from 74 patients. The lectin was detected in normal gastric epithelial cells and in all gastric carcinoma specimens, albeit in varying amounts. The L-31 level was significantly higher in the primary tumor than in adjacent normal tissue in 55% of the well-differentiated tubular carcinoma cases and in 50% of stage-III and -IV tumors. L-31 expression in liver metastases from well-differentiated tubular primary gastric carcinomas was higher in 31% of the cases relative to the corresponding primary cancers. Likewise, L-31 expression in metastases from poorly differentiated gastric carcinomas in lymph nodes was higher in 38% of the cases compared to the primary cancers. The higher expression of L-31 in primary cancers and metastases of certain types implicates this lectin in the metastatic phenotype, but the presence of L-31 in a primary cancer is not sufficient to allow the metastatic propensity of the tumor to be predicted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8112883     DOI: 10.1002/ijc.2910560404

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family.

Authors:  Z Z Su; J Lin; R Shen; P E Fisher; N I Goldstein; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis.

Authors:  P Nangia-Makker; Y Honjo; R Sarvis; S Akahani; V Hogan; K J Pienta; A Raz
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Decreased galectin-3 expression during the progression of cervical neoplasia.

Authors:  Jeong-Won Lee; Sang Yong Song; Jung-Joo Choi; Chel Hun Choi; Tae-Joong Kim; Jhingook Kim; Je-Ho Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-21       Impact factor: 4.553

5.  Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis.

Authors:  Afshin Teymoortash; Anna Pientka; Carsten Schrader; Markus Tiemann; Jochen A Werner
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-24       Impact factor: 4.553

Review 6.  Why anti-Bcl-2 clinical trials fail: a solution.

Authors:  Y Harazono; K Nakajima; A Raz
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

7.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

8.  Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells.

Authors:  Chui-Xue Huang; Yong-Hong Hou; Yun-Sheng Liu
Journal:  Neurosci Bull       Date:  2008-02       Impact factor: 5.203

9.  Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.

Authors:  Hafiz Ahmed; Francesco Cappello; Vito Rodolico; Gerardo R Vasta
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

10.  Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival.

Authors:  Axel S Merseburger; Mario W Kramer; Jörg Hennenlotter; Jürgen Serth; Stephan Kruck; Alfredo Gracia; Arnulf Stenzl; Markus A Kuczyk
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.